Key result
Colchicine cuts MACE ~25% vs. placebo in clinically manifest vascular disease.
Why the study?
Colchicine has emerged as a safe and inexpensive anti-inflammatory medication to target residual cardiovascular risk in secondary prevention, warranting re-evaluation with new RCT evidence.
Does colchicine reduce major adverse cardiovascular events in patients with clinically manifest vascular disease?
Meta-Analysis (n=21,800)
Does colchicine reduce major adverse cardiovascular events in patients with clinically manifest vascular disease?
Colchicine significantly reduces the risk of major adverse cardiovascular events, including MI and ischemic stroke, in patients with clinically manifest vascular disease.
Answers are grounded in this paper and cite their sources.
Supports colchicine in secondary vascular prevention; confirms prior RCTs with greater precision.
BACKGROUND AND AIMS: Colchicine has emerged as a safe and inexpensive anti-inflammatory medication to target the residual risk of cardiovascular events in the secondary prevention of coronary artery disease. Two recently published randomized controlled trials (RCTs) investigating colchicine in the post-stroke and post-myocardial infarction (MI) populations warrant a re-evaluation of colchicine. New evidence was synthesized in a systematic review and meta-analysis to determine the long-term efficacy and safety of colchicine for the secondary prevention of vascular disease. METHODS: Randomized controlled trials comparing the incidence of cardiovascular events between patients with clinically manifest vascular disease randomized to colchicine vs. placebo and ≥12-month follow-up were included. The primary efficacy endpoint is major adverse cardiovascular events (MACE) and includes cardiovascular mortality, MI, ischaemic stroke, and urgent coronary revascularization. The DerSimonian and Laird random effects model was used to calculate pooled effect estimates. RESULTS: Six RCTs, with a pooled sample size of 21 800 patients, were included (colchicine n = 10 871; placebo n = 10 929). Over a follow-up of 12-34 months, colchicine reduced the incidence of MACE compared with placebo [pooled hazard ratio .75, 95% confidence interval (CI) .56-.93]. The reduction in cardiovascular events among colchicine patients was driven by reductions in MIs, ischaemic strokes, and urgent coronary revascularizations (P < .05 for all). No differences were detected for safety outcomes (P > .05 for all), including non-cardiovascular deaths (risk ratio 1.08, 95% CI .76-1.54). CONCLUSIONS: This updated meta-analysis of RCTs demonstrated a substantial reduction in MACE, MI, ischaemic stroke, and recurrent coronary revascularization with colchicine compared with placebo. Therefore, the results support the use of colchicine to reduce recurrent cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Samuel et al. (2025) conducted a meta-analysis in clinically manifest vascular disease (n=21,800). Colchicine vs. Placebo was evaluated on major adverse cardiovascular events (MACE) including cardiovascular mortality, MI, ischaemic stroke, and urgent coronary revascularization (HR 0.75, 95% CI 0.56-0.93). Colchicine reduced the incidence of major adverse cardiovascular events compared with placebo in patients with clinically manifest vascular disease (pooled HR 0.75; 95% CI 0.56-0.93).
Synapse has enriched 10 related papers. Consider them for comparative context: